The effect of a Mediterranean diet <i>vs.</i> a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial

Akbulut, Ulaş Emre; Işık, İshak Abdurrahman; Atalay, Atike; Eraslan, Ali; Durmus, Emin; Turkmen, Sinem; Yurttas, Aziz Selcuk

doi:10.1080/09637486.2021.1979478

Cited by 15 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, clinicians should recommend lifestyle changes in people with overweight or obesity and NAFLD. A minimum weight loss goal of 5%, preferably $10% (113,114), is needed to improve liver histology, with fibrosis requiring the larger weight reduction to change (114)(115)(116). Individualized, structured weight loss and exercise programs offer greater benefit than standard counseling in people with NAFLD (107,117).…”

Section: Managementmentioning

confidence: 99%

4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023

ElSayed¹,

Aroda²,

Bannuru³

et al. 2022

Diabetes Care

119

165

View full text Add to dashboard Cite

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

show abstract

Section: Managementmentioning

confidence: 99%

4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023

ElSayed¹,

Aroda²,

Bannuru³

et al. 2022

Diabetes Care

119

165

View full text Add to dashboard Cite

show abstract

“…Recently, clinical trials have provided evidence of MD feasibility in adolescents and children with NAFLD. In children aged 9-17 years with NAFLD, the 12-week administration of MD could improve IR ( 17 ). Similarly, this diet plan could reduce the body mass index (BMI), fat mass, and hepatic steatosis, improve IR, and reduce the levels of transaminases, inflammatory markers, and oxidative stress markers in children aged 11-18 years with NAFLD ( 18 ).…”

Section: Treatment Strategies Of Nafldmentioning

confidence: 99%

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Zou

Wei

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.

show abstract

“…It is precisely the synergistic combinations of nutrients characterized by the protective substances they contain with the right water intake and the practice of physical activity that make the MD unique and beneficial to physical and mental health [76,109]. This diet is able to positively modulate all conditions associated with steatosis, including visceral obesity, insulin resistance, dyslipidemia, and chronic inflammation [110][111][112].…”

Section: Dietary Patternsmentioning

confidence: 99%

Nutritional Approaches in Children with Overweight or Obesity and Hepatic Steatosis

et al. 2023

View full text Add to dashboard Cite

Childhood obesity is a global public health problem. Worldwide, 41 million children under 5 years and 340 million children and adolescents between 5 and 19 years are overweight. In addition, the recent COVID-19 epidemic has further amplified this social phenomenon. Obesity is a condition associated with various comorbidities, such as nonalcoholic fatty liver disease (NAFLD). The pathophysiology of NAFLD in obesity is intricate and involves the interaction and dysregulation of several mechanisms, such as insulin resistance, cytokine signaling, and alteration of the gut microbiota. NAFLD is defined as the presence of hepatic steatosis in more than 5% of hepatocytes, evaluated by histological analysis. It can evolve from hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and end-stage liver failure. Body weight reduction through lifestyle modification remains the first-line intervention for the management of pediatric NAFLD. Indeed, studies suggest that diets low in fat and sugar and conversely rich in dietary fibers promote the improvement of metabolic parameters. This review aims to evaluate the existing relationship between obesity and NAFLD in the pediatric population and to assess the dietary patterns and nutritional supplementations that can be recommended to prevent and manage obesity and its comorbidities.

show abstract

The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: a randomized trial

Cited by 15 publications

References 39 publications

4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023

4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Care in Diabetes—2023

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Nutritional Approaches in Children with Overweight or Obesity and Hepatic Steatosis

Contact Info

Product

Resources

About